An Open-Label, Systemic Gene Delivery Study Using Commercial Process Material to Evaluate the Safety of and Expression From SRP-9001 in Subjects With Duchenne Muscular Dystrophy (ENDEAVOR)

Study Summary

Cohort 8 (non-ambulatory participants) is currently enrolling new participants. Enrollment for Cohorts 1 through 7 has been completed. This is an open-label gene transfer therapy study evaluating the safety of and expression from delandistrogene moxeparvovec in participants with Duchenne Muscular Dystrophy (DMD). The maximum participant duration for this study is 156 weeks.

Interventions

Study Locations

Facility	City	State	Country
Arkansas Children's Hospital	Little Rock	Arkansas	United States
University of California, San Diego	La Jolla	California	United States
University of California, Los Angeles	Los Angeles	California	United States
Stanford University	Palo Alto	California	United States
University of California, Davis	Sacramento	California	United States
University of Florida	Gainesville	Florida	United States
Ann & Robert H. Lurie Children's Hospital of Chicago	Chicago	Illinois	United States
Washington University in St. Louis	St Louis	Missouri	United States
Duke University Medical Center	Durham	North Carolina	United States
Nationwide Children's Hospital	Columbus	Ohio	United States
Neurology Rare Disease Center	Flower Mound	Texas	United States
Children's Hospital of The King's Daughters	Norfolk	Virginia	United States

Official Trial Information

View on ClinicalTrials.gov